Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hepatitis × Adrenal Cortex Hormones × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3 Neoplasms 3 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hemangioma 2 Radiation Pneumonitis 1 Radiation Injuries 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 Leukemia, Hairy Cell 1 Leukemia 1 Hepatitis 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Chemical and Drug Induced Liver Injury 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1 Brain Neoplasms 1

Interventions

Ursodeoxycholic Acid 1 Steroids 1 Sofosbuvir 1 Ribavirin 1 Prednisone 1 Mycophenolic Acid 1 Methylprednisolone Hemisuccinate 1 Methylprednisolone 1 Adrenal Cortex Hormones 1 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡